Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Gilead Sciences's Enterprise Value is $99,222 Mil.
Gilead Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $7,803 Mil. Therefore, Gilead Sciences's EV-to-EBIT ratio for today is 12.72.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Gilead Sciences's Enterprise Value is $99,222 Mil.
Gilead Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $10,496 Mil. Therefore, Gilead Sciences's EV-to-EBITDA ratio for today is 9.45.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Gilead Sciences's Enterprise Value is $99,222 Mil.
Gilead Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $27,115 Mil. Therefore, Gilead Sciences's EV-to-Revenue ratio for today is 3.66.
Gilead Sciences Enterprise Value Historical Data
The historical data trend for Gilead Sciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Gilead Sciences's Enterprise Value
For the Drug Manufacturers - General subindustry, Gilead Sciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's Enterprise Value falls into.
Gilead Sciences Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Gilead Sciences's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (NAS:GILD) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Gilead Sciences's current Enterprise Value is $99,222 Mil.
Gilead Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $7,803 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Gilead Sciences's current Enterprise Value is $99,222 Mil.
Gilead Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $10,496 Mil.
Gilead Sciences's current Enterprise Value is $99,222 Mil.
Gilead Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $27,115 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences Enterprise Value Related Terms
Thank you for viewing the detailed overview of Gilead Sciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Gilead Sciences (Gilead Sciences) Business Description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GILD has been successfully added to your 